{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:19:46Z","timestamp":1779909586092,"version":"3.53.1"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100017636","name":"Pfizer\u2019s Centers for Therapeutic Innovation","doi-asserted-by":"publisher","award":["ID#64130629"],"award-info":[{"award-number":["ID#64130629"]}],"id":[{"id":"10.13039\/100017636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Adults with relapsed or refractory (R\/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have dismal prognoses, underscoring the need for effective salvage therapies. Inotuzumab ozogamicin (INO) and blinatumomab (BLIN) have demonstrated efficacy in achieving complete remission (CR) and measurable residual disease (MRD) response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We tried to evaluate the clinical outcomes and toxicities of INO in adults with R\/R BCP-ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Prospective observational multicenter study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 100 patients (25 Ph-positive, 75 Ph-negative) received INO (0.8\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on week 1; 0.5\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on weeks 2\u20133) for the initial cycle, followed by 0.5\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      dosing in subsequent cycles. Allogeneic hematopoietic cell transplantation (allo-HCT) was planned after remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the cohort, 7 patients were primary refractory (4 post-BLIN), 36 relapsed after chemotherapy (23 post-BLIN), and 57 relapsed after allo-HCT (23 post-BLIN). Extramedullary relapse occurred in 39% of patients. After the first cycle, 60% achieved CR or CR with incomplete hematologic recovery; the overall best response rate after two cycles was 67%, with MRD negativity achieved in 63.1%. Thirty-nine patients (58.2%) underwent allo-HCT. Early mortality occurred in 12%, and hepatic veno-occlusive disease\/sinusoidal obstruction syndrome was observed in 10%. With a median follow-up of 31.5\u2009months, the 3-year overall survival was 21.3% in the entire cohort and 37.6% among transplanted patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>INO represents a potent salvage option for R\/R BCP-ALL. However, substantial toxicities highlight the critical need for careful patient selection and dose optimization strategies to maximize its therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>This study was registered in Clinical Research Information Service (CRIS #KCT0010009) which is connected to WHO ICTRP (Operated by Korea Centers for Disease Control and Prevention, Ministry of Health and Welfare, Republic of Korea).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251401046","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:18:06Z","timestamp":1765948686000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment outcome and toxicity analysis of inotuzumab ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: multicenter prospective observational study"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Seung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-Chan","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-9814","authenticated-orcid":false,"given":"Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Hematology, Mokdong Hospital, College of Medicine, Ewha Womans University, 1017, Anyangcheonro, Yangcheon-gu, Seoul 07985, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.217"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28930"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01097-6"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.407"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0051"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231154713"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25354"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144311"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3495-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2680"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.11.004"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02363-7"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221076762"},{"key":"e_1_3_4_22_2","volume-title":"An international system for human cytogenetic nomenclature","author":"Shaffer LG","year":"2009","unstructured":"Shaffer LG, Slovak ML, Campbell LJ, et al. An international system for human cytogenetic nomenclature S. Karger AG.: Basel, Switzerland, 2009."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.10.037"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0708-9"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03231-6"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017035"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.04.020"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211066176"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00077-3"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01444-2"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00073-X"},{"key":"e_1_3_4_33_2","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): updates from a phase II trial","volume":"41","author":"Nasnas CC","year":"2023","unstructured":"Nasnas CC, Jabbour E, Haddad F, et al. Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): updates from a phase II trial. J Clin Oncol 2023; 41(16 Suppl.): e19025.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022330"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011514"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251401046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251401046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251401046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:04Z","timestamp":1777591084000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251401046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"alternative-id":["10.1177\/20406207251401046"],"URL":"https:\/\/doi.org\/10.1177\/20406207251401046","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20406207251401046"}}